Search Results

You are looking at 1 - 10 of 13 items for :

  • SGLT2 inhibitors x
  • Refine by Access: All content x
Clear All
Open access

Gordon Sloan, Tania Kakoudaki, and Nishant Ranjan

Background Sodium glucose co-transporter 2 (SGLT-2) inhibitors are the latest guideline-approved therapy for the treatment of type 2 diabetes mellitus (NICE). Their attributes go beyond HbA1c reduction ( 1 ). Improvement in weight, blood

Open access

Frank Gao, Stephen Hall, and Leon A Bach

Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors such as empagliflozin, dapagliflozin, canagliflozin and ertugliflozin are increasingly used in the management of type 2 diabetes mellitus (T2DM), largely owing to their beneficial

Open access

Senhong Lee, Aparna Morgan, Sonali Shah, and Peter R Ebeling

antibody It is noteworthy that our patient was started on empagliflozin two days prior to his presentation with DKA. It has been reported in the literature that SGLT2 inhibitors may increase the risk of DKA shortly after their initiation ( 7

Open access

N Siddique, R Durcan, S Smyth, T Kyaw Tun, S Sreenan, and J H McDermott

metformin and a sulphonylurea and in the third case with an SGLT-2 inhibitor and lifestyle changes added to metformin. An association between improved glycaemic control and acute worsening of diabetic retinopathy is well described ( 1 ), but a

Open access

Mohammed Faraz Rafey, Arslan Butt, Barry Coffey, Lisa Reddington, Aiden Devitt, David Lappin, and Francis M Finucane

Background Sodium glucose-like transporter-2 inhibitor (SGLT2i) drugs have become widely prescribed for patients with type 2 diabetes (T2DM) because of their efficacy in improving glycaemic control ( 1 ), reducing cardiovascular and all

Open access

Arshpreet Kaur and Stephen J Winters

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a novel, insulin-independent treatment for diabetes that block glucose absorption in the proximal tubules of the kidney, increasing glucose excretion and lowering blood glucose

Open access

Michelle Maher, Mohammed Faraz Rafey, Helena Griffin, Katie Cunningham, and Francis M Finucane

Background Treatment of poorly controlled type 2 diabetes (T2DM) in patients with severe obesity is challenging. Not all affected individuals choose bariatric surgery or drug therapy ( 1 ). Only a small proportion of patients with severe

Open access

Tess Jacob, Renee Garrick, and Michael D Goldberg

Background Metformin is currently recommended by many professional organizations as the first-line agent for the treatment of type 2 diabetes ( 1 ). Its multiple advantages include potent glucose-lowering efficacy, absence of weight gain

Open access

Khaled Aljenaee, Osamah Hakami, Colin Davenport, Gemma Farrell, Tommy Kyaw Tun, Agnieszka Pazderska, Niamh Phelan, Marie-Louise Healy, Seamus Sreenan, and John H McDermott

the limitations of HbA1c testing and the mechanisms by which it may be affected by dapsone in particular. Case presentation Patient 1 A 34-year-old male was referred to the diabetes clinic with a presumptive diagnosis of type 2 diabetes

Open access

Prashanth Rawla, Anantha R Vellipuram, Sathyajit S Bandaru, and Jeffrey Pradeep Raj

patients. No history of SGLT-2 inhibitors usage in the above patients. Treatment She was treated with 5L of bolus IV normal saline to reverse the dehydration and was started on insulin drip according to the protocol for her blood glucose levels. She